Skip to content
Review Open access

High-Throughput Technologies for Targeted Covalent Drug Discovery: Recent Advances and Perspectives.

Sep 2026 · Chemistry · pp. e71680 · 0 citations · 77 references
Medicine

TL;DR

Recent advances in high-throughput strategies for targeted covalent drug discovery are reviewed, with a focus on phage display, mRNA display, DNA-encoded libraries, and artificial intelligence (AI)-assisted approaches.

Abstract

Covalent drugs have attracted increasing attention in modern drug discovery because of their prolonged target engagement, enhanced pharmacological efficacy, and potential to address traditionally challenging protein targets. The rapid development of electrophilic warhead chemistry, chemical biology methods, and high-throughput screening technologies has shifted covalent drug discovery from serendipitous identification to target-oriented and rational design. In recent years, phage display, mRNA display, and DNA-encoded library technologies have enabled the efficient de novo discovery of covalent peptides and small molecules, expanding the accessible chemical space for targeting cysteine, lysine, tyrosine, serine, and other reactive residues. Meanwhile, artificial intelligence has further accelerated covalent drug research by supporting covalent database construction, binding-site prediction, virtual screening, molecular generation, and structure-based ligand optimization. This article reviews recent advances in high-throughput strategies for targeted covalent drug discovery, with a focus on phage display, mRNA display, DNA-encoded libraries, and artificial intelligence (AI)-assisted approaches. We further discuss current challenges and future opportunities in the field and provide our perspectives on emerging directions for next-generation covalent ligand discovery.

Read PDF

Similar papers

#graph neural networks Review Open access Sep 2026

Antibody-drug conjugate engineering: from design to efficacy and safety

Antibody–drug conjugates (ADCs) represent a rapidly expanding class of targeted cancer therapeutics that combine the high selectivity of monoclonal antibodies with the potent cytotoxic activity of small-molecule drugs. Their clinical success relies on the simultaneous optimization of multiple interdependent parameters,...

Alberto Ocaña, J. R. Espinosa, C. Alonso-Moreno et al. · 0 citations
Review Open access Aug 2026

Cysteine-targeting covalent inhibition: Recent trends and emerging strategies.

Design and chemistry principles of cysteine-targeting covalent inhibitors are addressed, with a focus on the diversity of electrophilic warheads currently used or under research, and established motifs are discussed alongside newfound warheads.

Mariana Castelôa, F. Borges, S. Benfeito et al. · 0 citations
Review Open access Oct 2026

Redefining drug discovery: AI-driven strategies for efficient cancer therapeutics

The potential of artificial intelligence in drug discovery and development, has been explored in this review, encircling several stages from identification of target to its clinical applications, followed by drug development approaches encompassing the future of artificial intelligence in the pharmaceutical sector.

Diptanu De, Sohini Chakraborty, Satarupa Banerjee · 0 citations
Review Sep 2026

Lysine-targeted covalent inhibitors: mechanistic advances, pharmacological perspectives and translational challenges.

Targeted covalent inhibitors can provide potent and durable target modulation, but their development has largely centered on cysteine. Lysine offers a complementary covalent handle because it is widely distributed across catalytic sites, ligand-binding pockets, allosteric regions, and protein-protein interaction interf...

Ming-Jin Luo, Lu-Yu Ma, Guo-Shun Luo et al. · 0 citations
Review Open access Sep 2026

Rational drug design, synthetic and artificial intelligence approaches for bioactive heterocycles: advances and perspectives.

This review covers advances in designing and synthesizing bioactive heterocycles, highlighting structure-based drug design (SBDD) and ligand-based drug design (LBDD) approaches with computational modeling and Artificial Intelligence (AI) to find potent, selective molecules with good Absorption, Distribution, Metabolism...

Debajit Dewan, Bhupender Nehra, R. Nath et al. · 0 citations
Sep 2026

De Novo Design of Targeted Drugs by Precisely Programming Multiple Molecular Binding.

The programmable DNA NFs establish a modular and generalizable paradigm for targeted drug design, upgrading weak or non-functional binders into effective inhibitors through rational spatial programming.

Chuang-Yuan Zhao, Yu Jin, Xue Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.